At IIMHE, we are committed to advancing research that improves health outcomes and strengthens clinical practice. Right now, you have an opportunity to play a direct role in shaping how sarcopenia is studied and treated worldwide.
A new Delphi study, “Towards a Core Outcome Set for Sarcopenia Intervention Studies: Delphi Study”, is underway. Led by Prof. Charlotte Beaudart (University of Namur, Belgium) and Dr. Dolores Sanchez-Rodriguez (CHU Brugmann, Belgium), this project follows the COMET (Core Outcome Measures in Effectiveness Trials) initiative framework. Its goal is to build consensus on a Core Outcome Set (COS) for sarcopenia clinical trials.
Why does this matter?
At present, clinical trials on sarcopenia often measure different outcomes, making it difficult to compare results and draw meaningful conclusions. By establishing a common COS—with additional sub-COS tailored to interventions such as pharmacological, nutritional, or exercise-based therapies—we can ensure that future studies speak the same language. This will make research more consistent, comparable, and ultimately more impactful for patients.
What does participation involve?
- Two online survey rounds (about 15 minutes each).
- Hosted on the secure Welphi platform.
- You will be asked to rate the importance of outcomes in several domains, and you may suggest additional outcomes.
- A final consensus meeting with the working group will refine and confirm the results.
To take part, simply click here: Join the Delphi Study
Participation only requires creating a login with your email address and password.
Who should get involved?
If you are an expert in sarcopenia—whether your expertise lies in clinical care, research, or related interventions—your input is invaluable. The study team also encourages you to share this invitation with colleagues who might wish to contribute.
Questions?
For further information, please contact Ms. Sophie Van Heden at sophie.vanheden@unamur.be.
By adding your voice, you will help set the standard for future sarcopenia trials—ensuring better research and, ultimately, better care for patients.
